Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S412916-5mg | 5mg | In stock | $162.90 | |
S412916-10mg | 10mg | In stock | $271.90 | |
S412916-25mg | 25mg | In stock | $489.90 | |
S412916-50mg | 50mg | In stock | $706.90 | |
S412916-100mg | 100mg | In stock | $1,033.90 | |
S412916-250mg | 250mg | In stock | $2,326.90 |
Specifications & Purity | 95% |
---|---|
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of unc-51 like autophagy activating kinase 1;Inhibitor of unc-51 like autophagy activating kinase 2 |
Product Description | Information SBP-7455 (compound 26) is a dual inhibitor of ULK1 and ULK2 that potently inhibits ULK1/2 enzymatic activity in vitro and in vivo. SBP-7455 inhibits starvation-induced autophagic flux in TNBC cells. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-N-cyclopropyl-2-N-(3,4-dimethoxyphenyl)-5-(trifluoromethyl)pyrimidine-2,4-diamine |
---|---|
INCHI | InChI=1S/C16H17F3N4O2/c1-24-12-6-5-10(7-13(12)25-2)22-15-20-8-11(16(17,18)19)14(23-15)21-9-3-4-9/h5-9H,3-4H2,1-2H3,(H2,20,21,22,23) |
InChi Key | BQROJYIEHOOQBY-UHFFFAOYSA-N |
Canonical SMILES | COC1=C(C=C(C=C1)NC2=NC=C(C(=N2)NC3CC3)C(F)(F)F)OC |
Isomeric SMILES | COC1=C(C=C(C=C1)NC2=NC=C(C(=N2)NC3CC3)C(F)(F)F)OC |
PubChem CID | 132178569 |
Molecular Weight | 354.33 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2212141 | Certificate of Analysis | Nov 04, 2022 | S412916 |
L2212142 | Certificate of Analysis | Nov 04, 2022 | S412916 |
L2212143 | Certificate of Analysis | Nov 04, 2022 | S412916 |
L2212144 | Certificate of Analysis | Nov 04, 2022 | S412916 |
L2212145 | Certificate of Analysis | Nov 04, 2022 | S412916 |
L2212146 | Certificate of Analysis | Nov 04, 2022 | S412916 |
Starting at $241.90
1. Ren H, Bakas NA, Vamos M, Chaikuad A, Limpert AS, Wimer CD, Brun SN, Lambert LJ, Tautz L, Celeridad M et al.. (2020) Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.. J Med Chem, 63 (23): (14609-14625). [PMID:33200929] |